Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 76Neoplasms 29Thyroid Neoplasms 11Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 10Thyroid Carcinoma, Anaplastic 9Glioma 9Brain Neoplasms 9Multiple Myeloma 7Colorectal Neoplasms 7Skin Neoplasms 6Hematologic Neoplasms 6Thyroid Cancer, Papillary 4Ameloblastoma 4Lung Neoplasms 3Histiocytosis, Langerhans-Cell 3Glioblastoma 3Astrocytoma 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Ganglioneuroma 2

Interventions

trametinib 1spartalizumab 1pembrolizumab 1motesanib diphosphate 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1cediranib 1Sorafenib 1Sodium Iodide 1Lenalidomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × dabrafenib × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡